BRIEF-Pfizer Says Net Cost Savings From Now Expected To Reach $6.7 Billion Through 2029

Aug 4 (Reuters) - Pfizer Inc PFE.N:

• PFIZER: EXPECT A PIVOTAL TRIAL START THIS YEAR INVESTIGATING NURTEC’S USE AS A TREATMENT FOR CHRONIC MIGRAINE- PREPARED REMARKS

• PFIZER - AIM DELIVERING RISK-ADJUSTED HIGH SINGLE-DIGIT REVENUE CAGR FROM YEAR-END 2028 THROUGH YEAR-END 2033- PREPARED REMARKS

• PFIZER - WE NOW EXPECT AN ADDITIONAL $1 BILLION IN SAVINGS FROM OUR ONGOING COST REALIGNMENT PROGRAM- PREPARED REMARKS

• PFIZER: NOW EXPECT TOTAL NET COST SAVINGS OF APPROXIMATELY $3 BILLION FROM PROGRAM THROUGH 2029

• PFIZER - POWERED IN PART BY RAPID ADVANCEMENT OF TECHNOLOGY, NET COST SAVINGS FROM NOW EXPECTED TO TOTAL $6.7 BILLION THROUGH 2029 - PREPARED REMARKS

• PFIZER: EXPECT POST-2028 CASH FLOW TO BENEFIT FROM PREVIOUSLY ANNOUNCED VYNDAMAX PATENT SETTLEMENT

• PFIZER - TARGETING FIRST BEROBENATIDE APPROVAL IN 2028 - PREPARED REMARKS

• PFIZER: ALREADY SEEING BENEFITS FROM AI IN REDUCING COSTS & EXPANDING YIELDS IN MANUFACTURING- PREPARED REMARKS

• PFIZER- PLAN TO ADVANCE PHASE 3 PROGRAM FOR BEROBENATIDE THAT INCLUDES 10 STUDIES FOR CHRONIC WEIGHT MANAGEMENT, OBESITY-RELATED CONDITIONS THIS YEAR

Further company coverage: PFE.N